Yazar "Emir, I." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    RELATIONSHIP BETWEEN METABOLIC SYNDROME AND INFLAMMATION IN PERITONEAL DIALYSIS PATIENTS
    (Sage Publications Inc, 2012) Borazan, A.; Ucar, E.; Gursu, M.; Emir, I.; Ozturk, Y.
    We aimed to investigate the relationship between inflammation and metabolic syndrome as defined by the National Cholesterol Education Program Adults Treatment Panel III (NCEP-ATP III) diagnostic criteria in peritoneal dialysis patients. Ninety-four patients treated with peritoneal dialysis were included in the study. Patients' age, sex, weight, waist circumference, arterial blood pressure, fasting blood glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, C-reactive protein, albumin, uric acid and fibrinogen levels were recorded. Fourty-one patients diagnosed with metabolic syndrome and 53 peritoneal dialysis patients without metabolic syndrome were identified. In the metabolic syndrome group mean decrease in serum albumin and mean increase in C-reactive protein and fibrinogen was significantly different from the other group (p < 0.05, p < 0.05, p < 0.05, respectively). When gender, diabetes mellitus, and hypertension status were evaluated, the difference was not significant (p > 0.05). Peritoneal dialysis patients with metabolic syndrome should also be assessed for inflammation.
  • Küçük Resim
    Öğe
    Seroprevalence of hepatitis C in patients with type 2 diabetes mellitus and non-diabetic on haemodialysis
    (Wiley, 2006) Ocak, S.; Duran, N.; Kaya, H.; Emir, I.
    Type 2 diabetes mellitus (DM) has emerged as the commonest cause of end-stage renal disease. Haemodialysis (HD) treatment constitutes a high-risk environment for the transmission of hepatitis C virus (HCV). The aim of this study was to establish a potential relationship between type 2 DM and HCV infection in HD patients. Of the 267 HD patients, 67 (25.1%) had type 2 DM and 200 (74.9%) were with diverse aetiology for end-stage renal disease. The serum markers of HCV infection were tested by a second-generation enzyme-linked immunosorbent assay test for, antibodies and by qualitative reverse-transcription polymerase chain reaction technique for viral RNA. The overall prevalence of anti-HCV antibodies and HCV RNA was found to be 12.7% (34/267) and 10.1% (27/267), respectively. Patients with type 2 DM were found to have a higher HCV prevalence compared with non-diabetic patients [20.8% (14/67) vs. 10% (20/200)] (p < 0.05). The mean period on dialysis of anti-HCV-positive patients with type 2 DM was shorter than that observed for anti-HCV-positive non-diabetic patients (43.9 +/- 9.8 months vs. 59.7 +/- 28.4 months) (p < 0.05). This study has shown that although the period on dialysis of diabetic patients are shorter than non-diabetic patients, the prevalence of HCV in HD patients with type 2 DM is higher than that detected in non-diabetic HD patients.